An Open-Label, Multicenter, Single-Arm, Phase II Study to Assess the Efficacy and Safety of Alectinib in Patients With ALK-Rearranged Non−Small Cell Lung Cancer After Disease Progression on Prior ALK Inhibitor Therapy
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Alectinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ATALK
- Sponsors Roche
- 20 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 30 Jun 2017 Status changed from not yet recruiting to recruiting.
- 09 Jun 2017 Planned End Date changed from 29 May 2020 to 28 May 2020.